Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Berenberg lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Hold rating on the shares. The firm thinks BioNTech’s ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

The post Market Analysis: November 17th, 2025 appeared first on Stock Target Advisor.

Since May 2025, Pfizer (PFE) traded in a narrow range between $24.00 and $26. The company does not have shareholder ...

Jeffrey Gundlach, CEO of DoubleLine Capital, warned in a podcast appearance Monday that private credit "has the same ...

Economic cost of L.A. wildfires expected to keep rising, Bezos suffers rocket launch setback in space race with Musk, more news to start your day. The Edge specializes in special situations such as ...

The healthcare sector is heterogeneous, with a wide dispersion in returns between the best- and worst-performing stocks. Active management can pay off. Occidental rises ahead of earnings, Delta sinks ...

Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.